|
| A systematic review of Shenyan Kangfu Tablet in the treatment of henoch-schonlein purpura nephritis |
| Hits 153 Download times 151 Received:March 20, 2024 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2024.08.10 |
| Key Words
Shenyan Kangfu Tablet;henoch-schonlein purpura nephritis;clinical efficacy;systematic review;Meta analysis |
| Author Name | Affiliation | E-mail | | HU Zhi | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | PANG Wentai | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | JIN Xinyao | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHANG Yazi | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | SONG Wenting | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Yuetong | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | YANG Fengwen | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | 13682027022@163.com |
|
| Abstract
|
| [Objective] To evaluate the clinical efficacy and safety of Shenyan Kangfu Tablet in the treatment of henoch-schonlein purpura nephritis. [Methods] The randomized controlled trials（RCTs） of Shenyan Kangfu Tablets in the treatment of henoch-schonlein purpura nephritis were retrieved from CNKI，VIP，Wanfang，SinoMed，PubMed，Cochrane Library and Web of Science from the establishment of the database to June 20，2023. Two reviewers independently screened literatures，extracted the data，and assessed the risk of bias of the studies by using the bias risk assessment tool ROB2 recommended by Cochrane，and then cross-checked. RevMan 5.4 software was used for statistical analysis to systematically evaluate the efficacy and safety of Shenyan Kangfu Tablets in the treatment of henoch-schonlein purpura nephritis. [Results] Nine articles were included，with a total sample size of 853 cases. Of the overall risk of bias，2 studies were rated as high risk of bias and 7 studies were rated as having some risk of bias. The results of Meta-analysis showed that Shenyan Kangfu Tablets could improve the clinical efficacy in the treatment of patients with henoch-schonlein purpura nephritis [RR=1.19，95%CI（1.10，1.30），P<0.00 01]，reduce the 24-h urine protein quantification [SMD=-0.78，95%CI（-1.01，-0.56），P<0.000 01]，improve the efficacy of proteinuria [RR=2.23，95% CI（1.77，2.83），P<0.000 01]，reduce the urine red blood cell count [SMD=-0.70，95%CI（-1.04，-0.37），P<0.00 01]，and improve the efficacy of hematuria [RR=1.66，95%CI（1.05，2.60），P=0.03]. The adverse events of Shenyan Kangfu Tablets combined with conventional western medicine were fewer. [Conclusion] Shenyan Kangfu Tablet is safe and effective in the treatment of patients with henoch-schonlein purpura nephritis，which is limited by the number and quality of included studies. This conclusion needs to be verified by more high-quality studies. |
|
|
|
|
|
|
|
